This is the authors' abstract. We don't add key points for this paper.
light chains with high specificity and was designed to neutralize soluble toxic light chain aggregates and promote phagocytic clearance of deposited amyloid. Post hoc analyses from the Phase 3 VITAL trial suggested birtamimab plus standard of care confers a survival benefit in patients with advanced (Mayo Stage IV) AL amyloidosis. AFFIRM-AL (NCT04973137), a Phase 3 confirmatory trial of birtamimab plus standard of care in patients with Mayo Stage IV AL amyloidosis, is ongoing. This review summarizes birtamimab's mechanism of action, attributes, and potential clinical utility.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Palladini et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: